Discounted Cash Flow (DCF) Analysis Levered
ReShape Lifesciences Inc. (RSLS)
$0.59
-0.02 (-3.48%)
All numbers are in Millions, Currency in USD
Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.61 | 15.09 | 11.30 | 13.60 | 11.24 | 77.69 | 537.04 | 3,712.20 | 25,659.78 | 177,367.75 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (%) | ||||||||||
| Operating Cash Flow | -27.49 | -14.20 | -8.55 | -15.37 | -21.90 | -778.29 | -5,379.79 | -37,186.67 | -257,044.88 | -1,776,767.59 |
| Operating Cash Flow (%) | ||||||||||
| Capital Expenditure | -0.05 | -0.01 | -0.39 | -0.35 | -0.13 | -2.40 | -16.62 | -114.85 | -793.91 | -5,487.73 |
| Capital Expenditure (%) | ||||||||||
| Free Cash Flow | -27.54 | -14.21 | -8.94 | -15.73 | -22.03 | -780.70 | -5,396.41 | -37,301.52 | -257,838.79 | -1,782,255.32 |
Weighted Average Cost Of Capital
| Share price | $ 0.59 |
|---|---|
| Beta | 1.543 |
| Diluted Shares Outstanding | 0.42 |
| Cost of Debt | |
| Tax Rate | 0.82 |
| After-tax Cost of Debt | 65.54% |
| Risk-Free Rate | |
| Market Risk Premium | |
| Cost of Equity | 11.720 |
| Total Debt | 0.17 |
| Total Equity | 0.25 |
| Total Capital | 0.42 |
| Debt Weighting | 40.58 |
| Equity Weighting | 59.42 |
| Wacc |
Build Up Free Cash Flow
Year A/P | 2018 Actual | 2019 Actual | 2020 Actual | 2021 Actual | 2022 Actual | 2023 Projected | 2024 Projected | 2025 Projected | 2026 Projected | 2027 Projected |
| Revenue | 0.61 | 15.09 | 11.30 | 13.60 | 11.24 | 77.69 | 537.04 | 3,712.20 | 25,659.78 | 177,367.75 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -27.49 | -14.20 | -8.55 | -15.37 | -21.90 | -778.29 | -5,379.79 | -37,186.67 | -257,044.88 | -1,776,767.59 |
| Capital Expenditure | -0.05 | -0.01 | -0.39 | -0.35 | -0.13 | -2.40 | -16.62 | -114.85 | -793.91 | -5,487.73 |
| Free Cash Flow | -27.54 | -14.21 | -8.94 | -15.73 | -22.03 | -780.70 | -5,396.41 | -37,301.52 | -257,838.79 | -1,782,255.32 |
| WACC | ||||||||||
| PV LFCF | -584.53 | -3,025.19 | -15,656.60 | -81,029.40 | -419,360.83 | |||||
| SUM PV LFCF | -519,656.54 |
Terminal Value
| Growth in perpetuity method: | |
|---|---|
| Long-term growth rate | |
| WACC (%) | 33.56 |
| Free cash flow (t + 1) | -1,817,900.43 |
| Terminal Value | -5,760,140.77 |
| Present Value of Terminal Value | -1,355,348.70 |
Intrinsic Value
| Enterprise Value | -1,875,005.25 |
|---|---|
| Net Debt | -3.68 |
| Equity Value | -1,875,001.56 |
| Shares Outstanding | 0.42 |
| Equity Value Per Share | -4,418,109.67 |